Posts Tagged ‘CYTK’

ROL rolls, C rocks, CYTK rocky

Monday, December 13th, 2010

Rollins Inc. (NYSE: ROL) took on 54.44 percent Monday to come out of the starting blocks at $19.84. Volume was 75,263 shares, making headway on its normal daily average of 177,065. Atlanta-based Rollins is a premier North American consumer and commercial services company.

Citgroup Inc. (NYSE: C) proved among the volume leaders early Monday, trading in a brisk 130,924,832 shares, about a quarter its normal daily average of 530,261,000. Citigroup’s price inched up 0.21 percent to $4.78. CitiMortgage, Inc. has announced plans for an upcoming Mortgage Assistance Call-a-thon to take place from 7:00 AM December 15, 2010 until 1:00 AM on the morning of December 16, Eastern Standard Time. For the event, CitiMortgage (CMI) customers who have concerns about their ability to pay their mortgage can call into the company’s foreclosure prevention centers for information and advice.

Cytokinetics Inc. (NasdaqGM: CYTK) went south 19.45 percent to $2.36 soon after Monday’s opening. Volume for CYTK was 617,809, more than double its usual full-day volume. CYTK, based in San Francisco, announced the successful completion of its Phase IIa “Evidence of Effect” (EoE) clinical trial of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, during an oral presentation included in the Clinical Trials Session at the 21st International Symposium on ALS/MND in Orlando, Florida.